
Opinion|Videos|March 4, 2025
Long-Term Use of Topical Treatments in Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD, Randy Alevi, DO
Panelists discuss how the newer topical agents (PDE4 inhibitors, JAK inhibitors) demonstrate comparable efficacy to midpotency corticosteroids but with improved safety profiles, lacking steroid-related adverse effects such as skin atrophy, hypothalamic-pituitary-adrenal axis suppression, and tachyphylaxis when used long term.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the long-term efficacy and safety profiles of these newer agents compare with topical corticosteroids?
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Inequities in MHT Prescribing Run Deep: A Conversation With Wake Forest's Anna Christine Cochrane, MD
2
Mayo Clinic Researcher on How Hormone Therapy May Influence Weight Loss Outcomes With Tirzepatide
3
Mathematical Model Forecasts Diabetes Complications 15 Years Out, Confirms Legacy Effect of Early Control
4
Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS
5







































































































































































































































































































